In a previous dose escalation trial we demonstrated dose related survival correlation to Belagenpumatucel-L. In order to further evaluate safety and response at the previously defined optimal dose and schedule and to gain preliminary evidence on a hypothesis that the level of circulating tumor cells (CTCs) in blood may correlate with the overall survival of patients with stage IV NSCLC, we initiated a phase II trial. Patients received intradermal immunization of 2.5 Â 10 7 transfected allogeneic tumor cells (Belagenpumatucel-L, supplied by NovaRx) 1 Â every month for a total of 16 months. Circulating tumor cells (Veridex, Raritan, NJ) were measured every 4 weeks. Twenty-one advanced NSCLC patients were enrolled on this study. No significant toxic effect was observed. Overall survival was 562 days. The median survival was 660 days in patients having less than 2 CTCs at baseline compared to 150 days in patients with 2 or more CTCs (P ¼ 0.025). Phase II results of safety and response are consistent with prior experience following treatment with Belagenpumatucel-L and there is a suggestion that the number of circulating tumor cells at baseline appears to correlate with overall survival. A larger clinical trial is warranted to further explore this observation.
Introduction
Elevated levels of TGF-b2 are linked to immunosuppression in cancer patients, [1] [2] [3] [4] [5] [6] and the level of TGF-b2 is inversely correlated with prognosis in patients with NSCLC. 7 TGF-b2 also has antagonistic effects on Natural Killer cells, lymphokine activated killer cells and dendritic cells. [8] [9] [10] [11] [12] [13] Immunotherapy with Belagenpumatucel-L, a vaccinate produced from irradiated allogeneic non small cell lung cancer (NSCLC) cells transfected with a TGF-b2 antisense gene plasmid, previously demonstrated safety and a dose related survival advantage in patients with advanced NSCLC. 14 The optimal dose and schedule of Belagenpumatucel-L was defined as 2.5 Â 10 7 cells/injection administered 1 Â per month via intradermal injection. We now report results of a phase II study using the optimal dose and schedule of Belagenpumatucel-L in advanced NSCLC patients in whom standard therapy was not successful.
Materials and methods

Study design
This was an open-label, Phase II study designed to expand the safety and efficacy evaluation of Belagenpumatucel-L and to explore the correlation of circulating tumor cell (CTC) number with survival outcome. Patients received one intradermal injection of vaccine per month (2.5 Â 10 7 cells/injection) for 16 months or until disease progression.
Tumor staging was performed at baseline then every 4 months thereafter. Patients were serially monitored for circulating tumor cells at baseline and then every 4 weeks. Toxicity was monitored throughout the study. Patients demonstrating benefit from treatment at 16 weeks could be given up to 12 additional vaccinations. All patients signed local IRB-approved informed consent.
Study population
Eligible patients for this study were 18 years or older with histologically confirmed stage IV NSCLC. Patients were required to have completed conventional therapy, have an ECOG performance status of p2, an absolute granulocyte count X1500/mm 3 , platelet count X100 000/mm 3 , total bilirubin p2 mg/100 ml, and AST and ALT p2 Â Upper Limit of Normal. Patients were not allowed to have had prior anticancer therapy within 30 days of study participation.
Circulating tumor cell (CTC) detection CTC's were identified utilizing the Veridex Cell Search System (Veridex, Raritan, NJ) following harvest of 7.5 ml of whole blood collected in 10 ml EDTA tubes provided by Immunicon Corp (Huntingdon Valley, PA), the technical details of which have been previously described. 15, 16 Briefly, at baseline and every four weeks following the first administration of Belagenpumatucel-L, 7.5 ml of blood were collected into 10 ml evacuated tubes (CellSave). Samples were processed locally at our facility. 
Investigational product
Belagenpumatucel (NovaRx Corporation, San Diego, CA) was provided in frozen (liquid nitrogen) vials (1 ml of material). Vials contained 2 Â 10 7 cells per cell line. Vaccine production and design of the antisense plasmid have been previously described. 14, 17 Briefly, the vaccine consists of cells derived from 4 NSCLC cell lines [1 adenocarcinoma (SK-LU-1), 2 squamous cell carcinomas (NCI-H 520 and Rh 2), and 1 large cell carcinoma (NCI-H 460)] which were transfected via electroporation using a TGF-b2 antisense gene plasmid. Each cell line was required to have 435% knockdown of TGF-b2 following transfection. All were irradiated with 10 000 cGy and then frozen.
Statistical methods
Statistical analyses were carried out to investigate adverse events and survival. Throughout all analyses the type I error rate was controlled at the 0.05 level. In analyzing adverse events, a 'severity' analysis approach was pursued. Survival was illustrated using the Kaplan-Meier survival estimator. Overall survival as well as survival differences based on baseline CTC levels of 0-1 or 41 were analyzed. Within each baseline CTC category, survival was further analyzed based on the change in CTCs at Week 16. For patients who had 0-1 CTCs at baseline, survival was looked at between patients whose CTCs elevated over 1 or stayed 0-1 at Week 16. For patients who had elevated CTCs at baseline, survival was analyzed between patients whose CTC increased or decreased by Week 16. All differences in survival between groups were tested using a Mantel-Cox log rank statistic.
Results
Twenty-one patients were entered into the trial between September 6, 2005 and January 16, 2008. Demographics are summarized in Table 1 . Toxicity was evaluable in all patients. A total of 117 vaccinations were administered.
Safety
Analysis of severity of adverse events demonstrated no grade 3, 4 AE's related to treatment. Two toxic events related to vaccine occurring at a X5% frequency were observed. Transient injection site erythema of grade 2 was observed in 3 patients and injection site induration was observed in 5 patients (2 grade 1, 3 grade 2).
Response
One patient withdrew consent after one treatment without evidence of progression and was considered unevaluable Figure 1 . Median survival of all patients was 562 days ( Table 2) . Percent of patients alive at 1 year was 58% and at 2 years was 36%. No partial or complete responses were observed. Reasons off study involved progression (n ¼ 15), patient request (n ¼ 3), investigator requirement (n ¼ 1) and lost to follow up (n ¼ 1). One patient completed all 16 injections planned.
Circulating tumor cell assessment All 21 patients had baseline assessment of CTC's ( Table 2 ). Detection of greater than one circulating cell at baseline was observed in 6 patients (one patient of these six was unevaluable due to withdrawal of consent after only one treatment). The median number of circulating tumor cells in the X2 CTC evaluable patients at baseline was 10, range 2-21. Based on Kaplan Meier estimates, median survival of the 5 evaluable patients with elevated CTC's was 150 days compared to median survival of 660 days for the 15 patients with 0-1 CTC's at baseline (P ¼ 0.025).
In looking at survival differences based on changes in CTC levels at Week 16, 5 patients of 20 were unevaluable for CTCs at Week 16 and not included in this part of the survival analysis.
Among patients who had 0-1 CTCs at baseline, the median survival for those whose CTCs stayed 0-1 at Week 16 was 660 days (n ¼ 11) compared to 234 days (n ¼ 1) in the patient whose CTC level elevated over 1 at Week 16. All patients who had elevated CTCs at baseline and evaluable CTCs at Week 16 (n ¼ 3) had decreased CTC levels at Week 16 with a median survival of 278 days.
Discussion
Historically, NSCLC has been regarded as a non-immunogenic cancer. 18 Although immunotherapy for lung cancer has yielded little benefit in humans, [19] [20] [21] preliminary results of more recent vaccine studies designed to enhance tumor antigen recognition have demonstrated suggestively improved outcome in subsets of patients. [22] [23] [24] [25] [26] In a prior study, 14 we defined a clear dose related effect of Belagenpumatucel in both early and late stage NSCLC patients. We also found an impressive survival advantage at dose levels X2.5 Â 10 7 cells/injection compared to 1.25 Â 10 7 cells/ injection, with an estimated 2-year survival of 47% in response to Belagenpumatucel in advanced stage NSCLC patients. This compares favorably to the historical 2-year survival rate of less than 20% for similarly staged patients. Confirmatory safety and similar prolonged survival results were observed in the current trial supporting the optimal dose previously recommended on the basis of the phase II trial (2.5 Â 10 7 cells per injection).
14 Preliminary data regarding CTC monitoring as a measure of predicting response to Belagenpumatucel-L was also collected in this study. Despite a small number of patients there appeared to be a correlation of CTC count to overall survival. Patients with a baseline of 0-1 CTC's had improved survival compared to patients X2 CTC's (P ¼ 0.025). Additionally, an increase in CTC's from a baseline low count demonstrated lower survival if elevated at week 16.
Although not completely characterized, CTC's are malignant epithelial cells that have detached from primary and/or metastatic solid tumor sites. Greater than 95% of CTC's harvested from patients show correlation with primary malignant genotype (marker gene, RT-PCR) or cyto-genetic pattern. 27, 28 These cells are not 16, 30 including NSCLC in which 20% of samples contained X2 CTC/7.5 ml. Correlation with survival, using the Veridex technology, has been demonstrated in breast cancer 15, 16 colorectal cancer 31 and castration resistant prostate cancer. 32 Animal studies have shown a correlation between the number of CTC's and the number of lung metastases and tumor burden 33 although this has not been confirmed in cancer patients where, in at least one study, a correlation between radiographic tumor volume and CTC's was not found. 34 If, with further studies, the number of CTC's proves not to be correlated with either the number of metastatic sites or the cumulative tumor burden, then other potential biological correlates will need to be explored including, but not limited to, adhesiveness, vascular permeability, and immune mediated interactions with both macroscopic tumor and circulating tumor cells. In a study of PSA RNA-loaded dendritic cells in 13 patients with metastatic prostate cancer, three patients were monitored for CTC's using an RT-PCR technique. 35 In all three, the number of CTC's temporarily declined below control background despite rising serum PSA levels. In two of the patients the reappearance of CTC's was associated with measurable disease progression whereas the third, with CTC's persisting but at below pretreatment levels, remains with stable disease. In contradistinction to a study in patients with active, measurable metastatic disease, Peoples assessed CTC's in 16 patients with disease-free node positive breast cancer patients receiving a preventive HER2/neu E75 preventive vaccine following multimodality therapy. 36 CTC's were detected at baseline in 88% of the patients. A reduction in both total CTC's and HER2/neu þ CTC's was demonstrated and persisted following vaccination.
In conclusion, the results of this study confirm the efficacy and safety of Belagenpumatucel-L vaccination as observed in the previous phase II trial.
14 Preliminary data also suggest that monitoring the number of circulating tumor cells at baseline as well as the pattern of change sequentially during the course of treatment may serve as an early time-point surrogate of overall survival and, therefore, warrants further clinical investigation.
